Randomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib versus Sunitinib in patients with metastatic renal cell carcinoma: PISCES study.
Escudier, B Porta, C Bono, P Powles, T Eisen, T Sternberg, C Gschwend, J De Giorgi, U Parikh, O Hawkins, Robert E
Escudier, B
Porta, C
Bono, P
Powles, T
Eisen, T
Sternberg, C
Gschwend, J
De Giorgi, U
Parikh, O
Hawkins, Robert E
Citations
Altmetric:
Abstract
Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.
Description
Date
2014-03-31
Publisher
Collections
Keywords
Type
Article
Citation
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib versus Sunitinib in patients with metastatic renal cell carcinoma: PISCES study. 2014: J Clin Oncol